

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1 1 (original): A lipid formulation, said lipid formulation comprising:
2 a lipid phase, said lipid phase comprising a neutral lipid and a member selected
3 from the group consisting of cationic lipids and mucoadhesive compounds;
4 an aqueous phase; and
5 a therapeutic agent.

1 2 (original): A lipid formulation in accordance with claim 1, wherein said neutral
2 lipid is a phospholipid.

1 3 (original): A lipid formulation in accordance with claim 2, wherein said
2 phospholipid is a soybean oil-based phospholipid.

1 4 (original): A lipid formulation in accordance with claim 2, wherein said
2 phospholipid is a member selected from the group consisting of phosphatidylglycerols (PG),
3 phosphatidylethanolamines (PE), phosphatidylserines (PS) and hydrogenated
4 phosphatidylcholines (PC).

1 5 (original): A lipid formulation in accordance with claim 4, wherein said
2 phospholipid is a phosphatidylcholine.

1 6 (original): A lipid formulation in accordance with claim 5, wherein said
2 phosphatidylcholine is a member selected from the group consisting of Phospholipon 90H,
3 Phospholipon 80H and mixtures thereof.

7 (original): A lipid formulation in accordance with claim 1, wherein said lipid phase comprises a cationic lipid.

8 (original): A lipid formulation in accordance with claim 7, wherein said cationic lipid is a member of the group consisting of stearylamine, DC-Cholesterol, dimethyldioctadecylammonium bromide, or 3B-[N',N'-dimethylaminoethane)-carbamol.

9 (original): A lipid formulation in accordance with claim 1, wherein said lipid phase comprises a mucoadhesive compound.

10 (original): A lipid formulation in accordance with claim 9, wherein said mucoadhesive compound is a member of the group consisting of Carbopol 934 P, polyaxomers, carbomers and plant lectins.

11 (original): A lipid formulation in accordance with claim 1, wherein said aqueous phase is a member selected from the group consisting of sterile water, sterile saline and sterile, isotonic aqueous buffer solutions.

12 (original): A lipid formulation in accordance with claim 11, wherein said aqueous phase is a sterile, isotonic aqueous solution buffered with borates, acetates, bicarbonates or phosphates in the pH range of 7.0 to 7.8.

13 (original): A lipid formulation in accordance with claim 1, wherein said lipid formulation comprises about 0.001 to about 10.000 wt % of said lipid phase and about 90.000 wt % to about 99.999 wt % of said aqueous phase.

14 (original): A lipid formulation in accordance with claim 1, wherein said lipid formulation comprises about 0.1 wt % of said lipid phase and about 99.0 wt % of said aqueous phase.

1 15 (original): A lipid formulation in accordance with claim 1, wherein said
2 therapeutic agent is present in said aqueous phase.

1 16 (original): A lipid formulation in accordance with claim 1, wherein a
2 therapeutically effective amount of said therapeutic agent is present in said lipid formulation.

1 17 (original): A lipid formulation in accordance with claim 1, wherein said lipid
2 formulation is a liposome.

1 18 (original): A lipid formulation in accordance with claim 1, further comprising
2 a preservative.

1 19 (original): A lipid formulation in accordance with claim 18, wherein said
2 preservative is an antioxidant.

1 20 (original): A lipid formulation in accordance with claim 19, wherein said
2 antioxidant is a member selected from the group consisting of tocopherol, tocopherol derivatives,
3 butylated hydroxyanisole and butylated hydroxytoluene.

1 21 (original): A lipid formulation in accordance with claim 18, wherein said
2 preservative is an anti-microbial agent selected from the group consisting of benzalkonium
3 chloride, benzethonium chloride, chlorobutanol, phenylethyl alcohol and cetyl pyridinium
4 chloride.

1 22 (original): A lipid formulation in accordance with claim 21, wherein said
2 anti-microbial agent is chlorobutanol.

1 23 (original): A lipid formulation in accordance with claim 1, further comprising
2 a modifying agent selected from the group consisting of cholesterol, stearylamine, cholesteryl
3 hemisuccinate, phosphatidic acids, dicetyl phosphate and fatty acids.

1 24 (original): A lipid formulation in accordance with claim 1, further comprising
2 a wetting agent.

1 25 (original): A lipid formulation in accordance with claim 24, wherein said
2 wetting agent is a member selected from the group consisting of polyoxyethylene, sorbitan
3 monolaurate and stearate.

1 26 (original): A lipid formulation in accordance with claim 1, further comprising
2 a thickening agent.

1 27 (original): A lipid formulation in accordance with claim 26, wherein said
2 thickening agent is a member selected from the group consisting of hydroxyethylcellulose,
3 hydroxypropylmethylcellulose, methylcellulose, polyvinyl alcohol and polyvinylpyrrolidone.

1 28 (original): A lipid formulation in accordance with claim 1, wherein said
2 therapeutic agent is a non-steroidal anti-inflammatory drug (NSAID).

1 29 (original): A lipid formulation in accordance with claim 30, wherein said
2 NSAID is a member selected from the group consisting ketoprofen, flurbiprofen, ibuprofen,
3 diclofenac, ketorolac, nepafenac, amfenac and suprofen.

1 30 (original): A lipid formulation in accordance with claim 30, wherein said
2 NSAID is diclofenac.

1 31 (currently amended): A method for treating an ophthalmic disorder in a
2 mammal, said method comprising administering to the eye of said mammal a lipid formulation,
3 said lipid formulation comprising:
4 a lipid phase, said lipid phase comprising a neutral lipid and a member selected
5 from the group consisting of cationic lipids and mucoadhesive compounds;
6 an aqueous phase; and

7 a therapeutic agent in accordance with claim 1, wherein said therapeutic agent in
8 said lipid formulation is useful for treating said ophthalmic disorder.

1 32 (original): The method in accordance with claim 31, wherein said ophthalmic
2 disorder is post-operative pain.

1 33 (original): The method in accordance with claim 31, wherein said ophthalmic
2 disorder is ocular inflammation.

1 34 (original): The method in accordance with claim 33, wherein said ocular
2 inflammation results from a member selected from the group consisting of iritis, conjunctivitis,
3 seasonal allergic conjunctivitis, acute and chronic endophthalmitis, anterior uveitis, uveitis
4 associated with systemic diseases, posterior segment uveitis, chorioretinitis, pars planitis,
5 masquerade syndromes including ocular lymphoma, pemphigoid, scleritis, keratitis, severe
6 ocular allergy, corneal abrasion and blood-aqueous barrier disruption:

1 35 (original): The method in accordance with claim 31, wherein said ophthalmic
2 disorder is post-operative ocular inflammation.

1 36 (original): The method in accordance with claim 35, wherein said post-
2 operative ocular inflammation results from a member selected from the group consisting of
3 photorefractive keratectomy, cataract removal surgery, intraocular lens implantation and radial
4 keratotomy.

1 37 (original): The method in accordance with claim 31, wherein said ophthalmic
2 disorder is a fungal or bacterial infection.

1 38 (original): The method in accordance with claim 31, wherein said ophthalmic
2 disorder is herpes ophthalmicus.

1 39 (original): The method in accordance with claim 31, wherein said ophthalmic
2 disorder is endophthalmitis.

1 40 (original): The method in accordance with claim 31, wherein said ophthalmic
2 disorder is intraocular pressure.

1 41 (original): The method in accordance with claim 31, wherein said therapeutic
2 agent is diclofenac.

1 42 (original): The method in accordance with claim 41, wherein said diclofenac
2 is diclofenac sodium.

1 43 (original): A method for treating or preventing ocular inflammation,
2 paracentesis-induced miosis, cystoid macular edema and mydriasis, said method comprising
3 administering a therapeutically effective amount of one or more non-steroidal anti-inflammatory
4 drugs encapsulated or contained within a liposome formulation, said liposome formulation
5 comprising 0.001 to 10.000 wt% lipid phase, and 90.000 to 99.999 wt% aqueous phase.

1 44 (original): The method in accordance with claim 43, wherein said liposome
2 formulation is applied topically, resulting in the transcorneal or transscleral passage or
3 introduction of one or more non-steroidal anti-inflammatory drugs into the eye.

1 45 (original): The method in accordance with claim 43, wherein said lipid phase
2 comprises 0.0 to 90.0 wt% of one or more active agents, 10.0 to 100.0 wt% phospholipid, 0.0 to
3 20.0 wt% antioxidant, and 0.0 to 20% modifying agents; and said aqueous phase comprises 0.0
4 to 10.0 wt% one or more active agents, 0.0 to 5.0 wt% anti-microbial preservative, and 90.0 to
5 100.0 wt% aqueous solution.

1 46 (original): The method in accordance with claim 45, wherein said active
2 agent(s) are non-steroidal anti-inflammatory drugs.

1 47 (original): The method in accordance with claim 46, wherein said non-
2 steroidal anti-inflammatory drugs are selected from the group consisting of ketoprofen,
3 flurbiprofen, ibuprofen, diclofenac, ketorolac, nepafenac, amfenac and suprofen.

1 48 (original): The method in accordance with claim 47, wherein said non-steroidal
2 anti-inflammatory drug is diclofenac.

1 49 (original): The method in accordance with claim 43, wherein said ocular
2 inflammation is a symptom of iritis, conjunctivitis, seasonal allergic conjunctivitis, post-
3 operative inflammation, acute and chronic endophthalmitis, anterior uveitis, uveitis associated
4 with systemic diseases, posterior segment uveitis, chorioretinitis, pars planitis, masquerade
5 syndromes including ocular lymphoma, pemphigoid, scleritis, keratitis, severe ocular allergy,
6 corneal abrasion, blood-aqueous barrier disruption or ocular trauma.

1 50 (original): The method in accordance with claim 49, wherein said post-
2 operative inflammation is caused by photorefractive keratectomy, cataract removal surgery,
3 intraocular lens implantation or radial keratotomy.

1 51 (original): A liposome formulation comprising: a therapeutic agent; 0.001 to
2 10.000 wt% of a lipid phase; and 90.000 to 99.999 wt% of an aqueous phase.

1 52 (original): The liposome formulation in accordance with claim 51, wherein
2 said lipid phase comprises a phospholipid.